Amazon quietly makes surprising move into weight-related problems | Official Website of Louis Velazquez, entrepreneur, finance guy and tech innovator

What if your weight-loss medication arrived the same day you were prescribed it? That’s the future Amazon is quietly building. And it could reshape how millions of people access treatment.

Through its growing health care arm, Amazon Pharmacy is now offering a newly approved weight-management pill from Eli Lilly and Company (LLY), marking a deeper push into one of the fastest-growing areas in medicine. Amazon Pharmacy is a subsidiary of Amazon (AMZN) launched on Nov. 17, 2020, offering pharmacy services in the United States.

The move may seem subtle at first glance. But step back and think about it for a second. Amazon is positioning itself to dominate not just how people shop, but how they manage their health.

“Amazon Pharmacy is reducing barriers for customers to access new weight management treatments like Foundayo,” said Tanvi Patel, Vice President and General Manager of Amazon Pharmacy, as reported by Business Wire.

Looking at this deeply, it isn’t just about convenience. This is about access, speed, and control in a market where demand is exploding.

Amazon expands into weight-loss treatment with GLP-1 pill rollout

Amazon Pharmacy is now offering Foundayo, a once-daily GLP-1 pill designed for adults dealing with obesity or weight-related conditions. If you also didn’t know, it can be taken at any time of day without food or water restrictions.

For patients, the experience looks very different from traditional pharmacy visits. Instead of waiting in line or dealing with delays, customers can check real-time availability, see transparent pricing, and have the medication delivered straight to their door, often the same day.

In many cases, insured users can access the treatment for as low as $1 per day, while cash-paying customers may pay around $5 per day. And here’s where Amazon’s edge becomes clear.

By leveraging its logistics network, the company is rolling out Same-Day Delivery across nearly 3,000 cities and towns, with plans to expand to about 4,500 locations by the end of the year. Even in remote areas, according to Amazon, delivery times are significantly shorter than traditional mail-order pharmacies.

The company is also testing something even more ambitious: in-office kiosks at select clinics that allow patients to pick up prescriptions within minutes after a doctor visit. So instead of asking, “When will my medication arrive?” the new question now becomes, “Why isn’t it here already?”

Amazon is positioning itself to dominate not just how people shop, but how they manage their health.

Shutterstock

Why Amazon’s move could reshape access to weight management care

This isn’t Amazon’s first step into the GLP-1 space. It has been delivering similar medications since 2021. But this latest rollout signals something bigger. The company is trying to remove one of the biggest barriers in health care: access.

Weight-loss treatments, especially GLP-1 drugs, have surged in popularity. But availability, cost, and delays often stand in the way. By combining transparent pricing, automatic coupon application, and fast delivery, Amazon is trying to simplify that process.

More Retail:

There’s also a broader strategy at play. Amazon is building a full health care ecosystem. This means more than just delivering medication. Through services like One Medical, you can receive evaluations, prescriptions, and ongoing care, all connected to its pharmacy platform.

That raises a possibility. Amazon could eventually control the entire patient journey, from diagnosis to treatment. That’s interesting, I’d say.

Amazon’s strong earnings also show momentum beyond retail

This health care push comes at a time when Amazon is already firing on multiple fronts.

In its fourth-quarter 2025 results reported on Feb. 5, 2026, the company reported massive growth.

Net sales reached $213.4 billion, up 14% year over year.
Operating income climbed to $25 billion.
Net income reached $21.2 billion.

Growth wasn’t limited to one segment.

North America sales rose 10% year over year (YoY) to $127.1 billion.
International revenue increased 17% YoY to $50.7 billion.
AWS segment sales jumped 24% YoY to $35.6 billion.

For the full year, Amazon generated:

$716.9 billion in revenue, a 12% increase
$80.0 billion increase in operating income
$77.7 billion in net income
Operating cash flow of $139.5 billion (an increase of 20%)

But here is a key detail that stands out and that you might have likely missed. The company is investing heavily in future growth areas, including artificial intelligence (AI) and health care, even if it means short-term pressure on free cash flow.

So when Amazon expands into areas such as weight management, it’s not a side project. It’s actually a part of a much larger long-term play.

Amazon’s stock performance also reflects the strength

Investors appear to be buying into that vision. While Amazon (AMZN) has posted a modest year-to-date return of about 0.03%, trading at around $231 and recovering from the broader market drop, its longer-term performance tells a stronger story.

According to Yahoo Finance, Amazon’s stock is up more than 20% in the past year and has surged 126% over the last three years, highly outperforming the broader market’s 66% gain over that period.

In fact, that strong performance suggests confidence in Amazon’s ability to keep expanding into new, high-growth markets. And health care may be one of its biggest opportunities yet. So although the move into weight-loss treatment might seem quiet, it carries big implications.

Through the move, Amazon is now tackling access, as one of health care’s most frustrating challenges.